Latest filing published 14 Aug 2026 for Rhythm Pharmaceuticals, INC., €275k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Yann Mazabraud on record concern Rhythm Pharmaceuticals, Inc., in the capacity of senior executive. We count 33 filings; the first trade dates from 11 February 2022 and the latest from 12 August 2026.
Every open-market trade on record is a sale: 18 sales worth €11.5M. Besides market trades, the filings include 1 share grant and 14 option exercises. 2026 to date brings no purchases and 6 sales.
Most recently, on 14 August 2026, the filings show an option exercise worth €275k in Rhythm Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
24 of 24 declarations